Projects per year
Personal profile
Research interests
- Oral drug delivery, bioavailability enhancement and lymphatic drug transport
- Lipid-based formulation design and assessment
- Intracellular drug transport pathways and nuclear targeting
- Nanomedicines, in particular dendrimer-based drug delivery
- Translation and commercialisation
Biography
Chris Porter is Sir John Monash Distinguished Professor and Director, Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, Melbourne. He completed his undergraduate and graduate studies at the University of Nottingham before moving to Australia in 1992. Subsequently, Chris’ research program has focused on understanding and quantifying drug absorption, distribution and elimination profiles and on developing the models and techniques to probe these interactions. A major interest has been the issues and problems surrounding the absorption of poorly water soluble, highly lipophilic drugs. In particular Chris' programs have explored the use of lipid-modified drugs and lipid based delivery systems to promote drug integration into endogenous lipid transport pathways in order to enhance oral bioavailability and stimulate lymphatic transport. His interests have also expanded into the mechanisms of cellular transport of lipophilic drugs. In parallel Chris has a long standing interest in the potential utility of dendrimers as drug delivery systems. Chris has published more than 270 peer reviewed papers in these areas, attracting >30,000 citations (h-index 89, Google Scholar) and is a Thompson ISI/Clarivate Highly Cited researcher (2015, 2016, 2018, 2024). His research programs have attracted ~$30m in funding from government and commercial organisations. He is an inventor on >15 patent families, many of which are the subject of licencing/assignment deals. The most significant of these are with PureTech Health/Seaport Therapeutics (Boston) to develop the Glyph® lymphatic targeting technology (currently in Phase 2 clinical trial) and Starpharma (Melbourne) to develop the DEP® dendrimer based delivery system (Phase 2 clinical trial). His group continues to collaborate closely with these organisations to progress the technologies. Chris is a current member of the Editorial Boards of ACS Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. He is a previous member of the Board of Scientific Advisors of CRS. He is a Fellow of the American Association of Pharmaceutical Scientists and the Royal Australian Chemical Institute.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Intracellular Binding Proteins
- Lipid-Based Formulation Design
- Lymphatic Drug Transport
- Nanomedicines
- Dendrimer-Based Drug Delivery
- Oral Drug Delivery
- Bioavailability Enhancement
- Polyethylene Glycol
- Dendrimer
- Poly L-Lysine
- Pharmacokinetics
- Biodistribution
Collaborations and top research areas from the last five years
-
Synergising nanoemulsion and lipid biomimetic design for advanced delivery
Trevaskis, N. (Primary Chief Investigator (PCI)), Porter, C. (Chief Investigator (CI)), Cao, E. (Chief Investigator (CI)) & Simpson, J. (Partner Investigator (PI))
Australian Research Council (ARC)
3/03/25 → 2/03/28
Project: Research
-
MMQPA: Monash-Moderna Quantitative Pharmacology Accelerator
Kirkpatrick, C. (Primary Chief Investigator (PCI)), Landersdorfer, C. (Chief Investigator (CI)) & Porter, C. (Chief Investigator (CI))
Monash University – Internal University Contribution
15/08/23 → 14/08/28
Project: Research
-
Development of novel mRNA products for clinical trials
Pouton, C. (Primary Chief Investigator (PCI)), Beilharz, T. (Chief Investigator (CI)), Carroll, J. (Chief Investigator (CI)), Porter, C. (Chief Investigator (CI)), Al-Wassiti, H. (Chief Investigator (CI)), Davidovich, C. (Chief Investigator (CI)), Johnston, A. (Chief Investigator (CI)) & Trevaskis, N. (Chief Investigator (CI))
10/05/23 → 2/10/28
Project: Research
-
The Victorian Pre-clinical mRNA Innovation Incubator (VPMII)
Porter, C. (Primary Chief Investigator (PCI)), Pouton, C. (Chief Investigator (CI)), Carroll, J. (Chief Investigator (CI)), Beilharz, T. (Chief Investigator (CI)), Purcell, D. (Chief Investigator (CI)), Caruso, F. (Chief Investigator (CI)), Trevaskis, N. (Chief Investigator (CI)), Johnston, A. (Chief Investigator (CI)), Davidovich, C. (Chief Investigator (CI)) & Knott, G. (Chief Investigator (CI))
23/06/22 → 22/06/25
Project: Research
-
Translating treatments for lymphatic dysfunction associated with organ failure
Phillips, A. R. J. (Primary Chief Investigator (PCI)), Windsor, J. A. (Chief Investigator (CI)), Tawhai, M. (Chief Investigator (CI)), Trevaskis, N. (Chief Investigator (CI)), Huang, W. (Chief Investigator (CI)), Astle, F. (Chief Investigator (CI)), Hickey, A. (Chief Investigator (CI)), Campbell, D. (Chief Investigator (CI)), Jiang, Y. (Chief Investigator (CI)), Green, C. R. (Chief Investigator (CI)), Burrowes, K. (Chief Investigator (CI)), Clarke, R. B. (Chief Investigator (CI)), Mirjalili, S. A. (Chief Investigator (CI)), Boyd, B. (Chief Investigator (CI)), Paton, J. F. R. (Chief Investigator (CI)), Clark, A. (Chief Investigator (CI)), Pendharkar, S. (Chief Investigator (CI)), Hong, J. (Chief Investigator (CI)) & Porter, C. (Chief Investigator (CI))
Health Research Council of New Zealand
1/09/21 → 31/08/26
Project: Research
-
Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability
Hu, L., Quach, T., Han, S., Lim, S. F., Yadav, P., Senyschyn, D., Trevaskis, N. L., Simpson, J. S. & Porter, C. J. H., 2016, In: Angewandte Chemie - International Edition. 55, 44, p. 13700 –13705 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access64 Citations (Scopus) -
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
Cao, E., Watt, M. J., Nowell, C. J., Quach, T., Simpson, J. S., De Melo Ferreira, V., Agarwal, S., Chu, H., Srivastava, A., Anderson, D., Gracia, G., Lam, A., Segal, G., Hong, J., Hu, L., Phang, K. L., Escott, A. B. J., Windsor, J. A., Phillips, A. R. J. & Creek, D. J. & 3 others, , 20 Sept 2021, In: Nature Metabolism. 3, 9, p. 1175-1188 14 p.Research output: Contribution to journal › Article › Research › peer-review
87 Citations (Scopus) -
Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief
Jensen, D. D., Lieu, T., Halls, M. L., Veldhuis, N. A., Imlach, W. L., Mai, Q. N., Poole, D. P., Quach, T., Aurelio, L., Conner, J., Klein Herenbrink, C., Barlow, N., Simpson, J. S., Scanlon, M. J., Graham, B., McCluskey, A., Robinson, P. J., Escriou, V., Nassini, R. & Materazzi, S. & 6 others, , 31 May 2017, In: Science Translational Medicine. 9, 392, 15 p., aal3447.Research output: Contribution to journal › Article › Research › peer-review
178 Citations (Scopus) -
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity
Trevaskis, N., Kaminskas, L. M. & Porter, C. J., 2015, In: Nature Reviews Drug Discovery. 14, 11, p. 781-803 23 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile547 Citations (Scopus) -
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
Porter, C. J., Trevaskis, N. & Charman, W. N., 2007, In: Nature Reviews Drug Discovery. 6, 14, p. 231 - 248 18 p.Research output: Contribution to journal › Article › Research › peer-review
1623 Citations (Scopus)
Prizes
-
-
Clarivate Analytics Highly Cited
Porter, C. (Recipient), 2018
Prize: Prize (including medals and awards)
-
-
-
Clarivate Analytics Highly Cited
Porter, C. (Recipient), 2024
Prize: Prize (including medals and awards)
-
Fellow of the American Association of Pharmaceutical Scientists
Porter, C. (Fellow)
2014 → …Activity: External Academic Engagement › Professional association or peak discipline body
-
Fellow of the Royal Australian Chemical Institute
Porter, C. (Fellow)
2009 → …Activity: External Academic Engagement › Professional association or peak discipline body
-
Starpharma Pty Ltd (External organisation)
Boyd, B. J. (Inventor), Kaminskas, L. M. (Inventor) & Porter, C. J. (Inventor)
7 Sept 2016Activity: Industry, Government and Philanthropy Engagement and Partnerships › Patents › Patent
-
Starpharma Pty Ltd (External organisation)
Boyd, B. J. (Inventor), Kaminskas, L. M. (Inventor) & Porter, C. J. (Inventor)
11 Nov 2016Activity: Industry, Government and Philanthropy Engagement and Partnerships › Patents › Patent
-
Starpharma Pty Ltd (External organisation)
Boyd, B. J. (Inventor), Kaminskas, L. M. (Inventor) & Porter, C. J. (Inventor)
15 Jul 2014Activity: Industry, Government and Philanthropy Engagement and Partnerships › Patents › Patent
Press/Media
-
New data showing enhanced lymphatic transport from Glyph prodrug platform
12/02/25
1 Media contribution
Press/Media: Article/Feature
-
Seaport raises $255m to develop Glyph Prodrug platform
21/10/24
1 Media contribution
Press/Media: Article/Feature
-
-
Relief in sight: Pain researchers announce breakthrough
Halls, M., Porter, C. & Canals, M.
1/06/17
1 item of Media coverage
Press/Media: Article/Feature
-
Monash pain treatment a 'game changer'
Halls, M., Porter, C., Canals, M. & Bunnett, N.
1/06/17
1 item of Media coverage
Press/Media: Article/Feature